Per the terms of the Inflation Reduction Act (IRA) signed into law Aug, 16, the payment for biosimilar drugs under Part B average sales price (ASP) reimbursement ticks up from 106% – the cost of the biosimilar plus a 6% provider reimbursement – to 108% starting this month.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
